Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Biofrontera Inc. Common Stock

BFRI

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.

Last trade $0.6301
Day change +$0.0601 (+10.54%)
Day range $0.55 – $0.675
Volume 181,956
Market cap $10M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$10.23M
Price / earnings
—
Price / book
-42.1×
Price / sales
0.21×
EV / sales
0.24×
EV / EBITDA
-1.8×

Profitability

Earnings per share
-$0.34
Return on assets
-28.6%
Return on equity
2,526.34%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-19.54×
Current ratio
0.78×
Quick ratio
0.66×
Cash ratio
0.23×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$5.55M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for BFRI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$9.07M$12M$10.08M$17.1M$6.99M$9.03M$8.59M$12.56M
Cost of revenue$2.32M$2.41M$2.12M$3.01M$2.05M$2.64M$3.27M$5.27M
Gross profit$6.75M$9.59M$7.97M$14.09M$4.94M$6.39M$5.32M$7.29M
Selling, general and administrative$12.49M$9.67M$11M$8.75M$10.37M$10.6M$8.66M$8.22M
Research and development$450K$448K$900K$787K$854K$870K$1.21M$783K
Total operating expenses$13.25M$10.12M$12.29M$9.53M$11.22M$11.47M$9.87M$9M
Operating income-$6.5M-$524K-$4.32M$4.56M-$6.28M-$5.08M-$4.55M-$1.71M
Interest expense-$128K-$126K-$125K$331K-$111K-$115K-$106K$2M
Income before taxes-$6.42M-$581K-$4.75M$5.64M-$6.64M-$5.3M-$4.2M-$1.4M
Income taxes$4K$23K$0$0$6K$21K-$1K-$3K
Net income-$6.42M-$604K-$4.75M$5.64M-$6.65M-$5.32M-$4.2M-$1.4M
Net income attributable to common shareholders-$6.42M-$604K-$4.75M$5.64M-$6.65M-$5.32M-$4.2M-$1.4M
EBITDA-$6.44M-$459K-$4.27M$4.62M-$6.26M-$5.05M-$4.52M-$1.68M
Basic earnings per share-$0.42-$0.05-$0.41$0.48-$0.62-$0.57-$0.47-$0.18
Diluted earnings per share-$0.42-$0.05-$0.41$0.48-$0.62-$0.57-$0.47-$0.18

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026

Biofrontera Inc. (NASDAQ: BFRI) announced it will report third quarter 2026 financial results on November 13, 2026, followed by a management conference call. The company, a biopharmaceutical firm focused on dermatological treatments using photodynamic therapy, recently received FDA approval in September 2026 for Ameluz® Red Light PDT to treat superficial basal cell carcinoma, marking the first and only photodynamic therapy approved in the U.S. for skin cancer treatment.

Zacks Investment Research

MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates

MannKind (MNKD) reported a quarterly loss of $0.07 per share, beating consensus estimates of $0.08 loss by 12.5%, with revenues of $101.87 million missing estimates by 3.5%. The stock has declined 30.7% year-to-date versus the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

Photodynamic Therapy Market: Durable Growth with a CAGR of 8.3% Through 2035

The global photodynamic therapy (PDT) market is expected to grow at a CAGR of 8.3% from 2023 to 2035, driven by minimally invasive treatment demand, expanding applications in oncology and dermatology, and technological innovations. North America is projected to grow at 14% CAGR, while Europe currently holds 50% market share. Over 70 PDT therapies are under clinical development, with challenges including limited tissue penetration and high system costs.

GlobeNewswire Inc.

Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026

Biofrontera Inc., a biopharmaceutical company specializing in photodynamic therapy (PDT), announced it will report Q1 2026 financial results on May 14, 2026, followed by a conference call at 11:00 a.m. ET. The company commercializes Ameluz® with RhodoLED® lamp series for treating actinic keratosis and is conducting clinical trials to expand use to non-melanoma skin cancers and acne.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 5, 20231-for-20reverse split